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A post-prandial increase in saturated fatty acids (SFAs) and glucose (Glc) activates an inflammatory response, which may be prolonged following restoration
of physiological SFAs and Glc levels — a finding referred to as ‘metabolic memory'.
This study examined chronic and oscillating SFAs and Glc on the inflammatory signalling pathway in human adipose tissue (AT) and adipocytes (Ads) and
determined whether Ads are subject to “metabolic memory.”
Abdominal (Abd) subcutaneous (Sc) explants and Ads were treated with chronic low glucose (L-Glc): 5.6 mM and high glucose (H-Glc): 17.5 mM, with low
(0.2 mM) and high (2 mM) SFA for 48 h. Abd Sc explants and Ads were also exposed to the aforementioned treatment regimen for 12-h periods, with alternating
rest periods of 12 h in L-Glc.
Chronic treatment with L-Glc and high SFAs, H-Glc and high SFAs up-regulated key factors of the nuclear factor-κB (NFκB) pathway in Abd Sc AT and Ads
(TLR4, NFκB; Pb.05), whilst down-regulating MyD88. Oscillating Glc and SFA concentrations increased TLR4, NFκB, IKKβ (Pb.05) in explants and Ads and up-
regulated MyD88 expression (Pb.05). Both tumor necrosis factor α and interleukin 6 (Pb.05) secretion were markedly increased in chronically treated Abd Sc
explants and Ads whilst, with oscillating treatments, a sustained inflammatory effect was noted in absence of treatment.
Therefore, SFAs may act as key instigators of the inflammatory response in human AT via NFκB activation, which suggests that short-term exposure of cells to
uncontrolled levels of SFAs and Glc leads to a longer-term inflammatory insult within the Ad, which may have important implications for patients with obesity
and Type 2 diabetes.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Keywords: Saturated fatty acids; Glucose; Obesity; Toll-like receptors; Human adipose tissue; Inflammation1. Introduction
Obesity and inflammation are highly integrated processes in the
pathogenesis of insulin resistance, Type 2 diabetes (T2DM) and
cardiovascular disease. Whilst it is clear that dietary habits are key
determinants in the development of obesity associated T2DM,
emerging evidence identifies distinct ‘cross-talk' between metabolic
and inflammatory processes during such pathogenesis [1–3]. Previous
findings have determined that postprandial hyperglycaemia is☆ The authors have nothing to disclose and state that there is no conflict
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Open access under CC BY-NC-ND license.strongly associated with macro-and micro-vascular complications,
with several studies identifying the role of glucotoxicity in oxidative
stress and the subsequent induction of inflammatory cytokines,
chemokines, reactive oxygen species and the nuclear factor-κB
(NFκB) signalling pathway, which includes activation of NFκB's
regulatory molecule, I kappa B kinase (IKKβ) [4–8]. Studies have
also observed that free fatty acids have the potential to activate the
innate immune signalling pathways, indicating a causative role for
both glucose and saturated fatty acids (SFAs) in the pathogenesis of
T2DM, via the initiation of these inflammatory processes [9–11].
In recent years the role of adipose tissue in the development of
inflammatory linked disease states has been established, with
numerous pro-inflammatory cytokines (adipocytokines) being
secreted from adipose tissue. These factors often have a duality of
function in their capacity to signal an organism's nutritional status
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tion of innate immune receptors- toll-like receptors (TLRs) — on
human and murine adipocytes — and their activation by bacterial
and fungal pathogens supports the theory that adipocytes have an
innate immune capacity. In conditions such as obesity and T2DM,
there are underlying subclinical inflammatory processes, which
adipose tissue appears central to, exacerbated by macrophage
infiltration, thus increasing the potential inflammatory response
from this tissue [12].
With prospective studies highlighting the presence of low grade
inflammation prior to the onset of T2DM or the metabolic
syndrome [13–16], understanding the mechanisms that propagate
this low level inflammatory state is key to unravelling its pathology.
In recent years, studies have suggested that SFAs act as ligands for
several members of the TLRs [10,11], leading to activation of
putative inflammatory pathways. Furthermore, hyperglycaemia also
mediates an inflammatory response, which may be perpetuated
long after the original insult- a phenomenon referred to as
“metabolic memory” [17–19]. As such, postprandial glucose and
lipids appear to increase oxidative stress, inflammation and the
production of free radicals [4–8,20], which may have a direct
impact on adipose cells as well as the endothelium [17–19]. Studies
indicate that inflammatory associated complications may arise
many years later as a consequence of the initial insult and
subsequent events [13–16,20,21].
As such, grazing dietary habits in pre-diabetic subjects may lead to
an almost continual chronic elevation of glucose and SFAs, which may
have a direct impact on the inflammatory response from adipose tissue,
which is exacerbated in conditionsofweight gain, insulin resistance and
overt T2DM. Hence, adipose tissue would become a source of
inflammatory response due to exposure to glucose and SFAs. Therefore,
the aims of these studies were to (1) examine whether chronic
exposure to glucose and/or SFAsmay have amore substantial impact on
human adipose to mediate inflammation, (2) examine the effect of
intermittent exposure to such insults and if they alleviate or exacerbate
such an inflammatory response and (3) determine whether the
adipocyte retains a metabolic memory of the insult, in its absence. To
examine this, specifically, we investigated whether chronic or oscillat-
ing exposure to glucose and SFA concentrations would promote the
TLR4/NFκB signalling pathway in human adipose tissue and/or isolated
adipocytes. Hence, in addition to observing TLR4 and NFκB protein
expression, we investigated key components of the TLR4/NFκB
intracellular signalling pathways, including MyD88, TRAF6 and IKKβ.
Furthermore, we also determined whether the effects induced by
glucose and SFAs and long-term or oscillating exposure are mediated
through both the c-Jun N terminal kinase (JNK) and NFκB pathways.
2. Methods and materials
2.1. Subjects
For the purposes of tissue culture, abdominal subcutaneous (Abd Sc) adipose
tissue was obtained from a cohort of female subjects (age: 45±3.3 years; body mass
index: 21.9±2.4 kg/m2, n=6). All human adipose tissue was obtained through
elective, liposuction surgery with informed consent, in accordance with guidelines of
the Coventry and Warwickshire ethics committee. Subjects providing fat samples
were not on endocrine therapy (e.g., steroids, HRT, thyroxine) or receiving any
antihypertensive therapy.
2.2. Isolation and cell culture of adipocyte and Abd Sc AT
As previously published [22], Abd Sc adipose tissue was initially washed with lysis
buffer [ammonium chloride (NH4Cl) 8.24g, potassium bicarbonate (KHCO3) 1.001g,
EDTA 0.5 M] to remove erythrocytes and leukocytes. The Abd Sc adipose tissue was
then separated from the blood fraction by centrifugation at 360×g for 30 s.
To isolate the Abd Sc adipocytes, the adipose tissue was washed with 1× Hank's
balanced salt solution (HBSS) containing penicillin (100 U/ml) and streptomycin
(100 μg/ml). All adipose tissue was digested with the same batch of collagenase class
1 (2 mg/ml, Worthington Biochemical) in 1× HBSS (Gibco, Paisley, UK) for between30 min and 1 h at 37°C in a water bath and shaken at 100 cycles per minute [23–
25]. The disrupted tissue was filtered through a double-layered cotton mesh and
pre-adipocytes and adipocytes separated by centrifugation at 360×g for 5 min.
Following centrifugation, the upper layer of mature adipocytes was removed from
the collagenase-dispersed preparation, washed in phenol red-free medium DMEM:F12
twice and centrifuged at 360×g for 2 min.
Abd Sc adipose tissue (500 μl) and Abd Sc adipocytes (500 μl, equivalent to 250,000
adipocytes) were placed in specialised permeable inserts within 12-well plates to
allow easy transfer of samples to new 12-well plates with fresh media. For the chronic
treatments, the samples were cultured in phenol red-free DMEM-F-12 medium
containing penicillin and streptomycin, in addition to low-glucose (L-Glc): 5.6 mM or
high glucose (H-Glc): 17.5 mM in combination with low (0.2 mM) and high (2 mM)
doses of a palmitate:stearic mix (referred to hereafter as SFA), as well as high glucose
alone 17.5 mM, for 48 h.
SFA was prepared as 40 mM stocks by dissolving Stearic:Palmitic acid Mixture
(Sigma-Aldrich, Cambridge, UK) in absolute ethanol and then lyophilising it. The
lyophilised SFA was re-constituted in 1 ml 3% bovine serum albumin (free fatty acid-
free) in Geys Buffer by vortexing and sonication. Abd Sc adipose tissue and adipocytes
maintained in L-Glc: 5.6-mM medium, as well as dissolving buffer without SFA, were
used as controls.
For the intermittent treatments, Abd Sc adipose tissue and Abd Sc adipocytes were
also cultured using the specialised permeable inserts within the wells of the 12-well
plates. The samples were then intermittently exposed to 12-h alternate phases of
control media incubation followed by the same previous glucose/SFA treatment, as
outlined for chronic treatment. Cell viability was then assessed according to previously
described methods [26]. Following incubation of adipocytes (37°C/5% CO2) with their
respective treatments, the conditioned media, adipocytes and adipose tissue were
separated by centrifugation (360×g for 2 min). The media were removed, aliquoted
and stored at −80°C.
Protein was extracted from isolated Abd Sc adipose tissue and adipocytes with
RIPA buffer. These samples were subsequently flash-frozen in liquid nitrogen, thawed
and spun at 1800×g for 30 min at 4°C. The resulting infranatant was extracted and
stored immediately at −80°C.2.3. Protein determination and Western blot analysis
Extracted protein was quantified via the Bio-Rad DC (detergent compatible)
protein assay kit (Bio-Rad, Hemel Hempstead, UK). Adipocyte and adipose tissue
protein samples were assessed to determine there was no significant statistical
variation between control and treatment regimens. Denatured protein samples (25–
50 μg/lane) were loaded onto a 10% gel and blotted onto a Hybond-P membrane
(GE Healthcare, Little Chalfont, UK). Following gel electrophoresis and electroblot-
ting, filters were incubated overnight at 4°C with continual motion, with
monoclonal NFκB Primary antibody (65 kDa, 1:250; Cambridge BioScience, Cam-
bridge, UK), polyclonal anti-JNK1 and two stress-activated protein kinase phos-
phospecifics (49 kDa, 55 kDa, 1:1,750, BioSource International) and MyD88 (32
kDa, 1:250, TCS Cell works, Buckingham, UK). Monoclonal antibody to TLR4 (97
kDa, 1:250, ABCAM, Cambridge, UK) and a monoclonal antibody to IKKβ (1:250,
TCS Cellworks, Buckingham, UK) followed by anti-mouse conjugated to horseradish
peroxidase secondary antibody (The Binding Site, Birmingham, UK) were used. A
chemiluminescent detection system ECL/ECL+ (Amersham, Little Chalfont, UK)
enabled visualization after exposure to X-ray film. Equal protein loading was
confirmed by actin Western blotting, as previously described [27]. Furthermore,
absence of contaminating cells (i.e., macrophages) in the isolated adipocytes was
confirmed via Western blot for CD45, a specific marker of mononuclear blood cells,
as outlined in previous studies [28]. Autoradiographs were quantified by
densitometry using Synoptics Group Gene tools Bio Imaging system software
(Syngene, Cambridge, UK) according to the manufacturer's guidelines. The bands
were first normalised as a function of the loading control (β-actin), then converted
to fold change compared with controls (untreated samples).2.4. Conditioned media cytokine assessment
Cytokine levels secreted into the media from Abd Sc adipose tissue and adipocytes
treated with varying glucose and SFA concentrations were measured. For this,
conditioned media was utilised in commercially available enzyme-linked immuno-
sorbent assay (ELISA)-based colorimetric kits to determine the quantities of interleukin
(IL)-6 and tumor necrosis factor α (TNFα) (QuantiGlo ELISA; R and D Systems,
Abingdon, UK).2.5. Statistical analysis
For assessment of protein expression and secretion, statistical analysis was
undertaken using analysis of variance for comparison of control versus treatments. The
threshold for significancewasPb.05. Data in the text and figures are presented asmean±S.D.
or mean±S.E.M. SPSS version 15 was used to perform the statistical analysis.
Fig. 1. (A–F) Themean relative protein expression (±S.E.M.) of TLR4, MYD88 and TRAF-6 in explants and isolated, mature adipocytes compared with their respective controls (explant
tissue and adipocyte cells maintained in L-Glc (5.6 mM), with representative Western blots shown above. Statistical analysis compared expression of the proteins in explants and cells
chronically treated with L-Glc: 5.6 mM or H-Glc: 17.5 mM in combination with low (0.2 mM) and high (2 mM) doses of a palmitate: SFA, as well as high glucose alone 17.5 mM, for 48
h (n=6; ⁎Pb.05, ⁎⁎Pb.01, ⁎⁎⁎Pb.001).
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3.1. Effects of chronic treatment with SFA and glucose on TLR4, MyD88
and TRAF-6 protein expression
TLR4 protein levels were significantly increased by exposure to H-
Glc (Pb.001) or by SFA treatment (explant: Pb.001, Ad: Pb.01), at
either concentration, compared with respective controls (L-Glc 5.6
mM) in both Abd Sc explants and isolated Abd Sc adipocytes (Fig. 1A
and 1B). Low SFA treatment was found to significantly reduce MyD88
expression in adipocytes in the presence of H-Glc (Pb.01), whereas
high SFA treatment suppressed MyD88 expression, independent of
glucose concentration, in adipocytes (Pb.01). Only H-Glc treatment
combined with high SFA treatment produced a decrease in MyD88
expression in explants, compared with control (Pb.01; Fig. 1C and
1D). In adipocytes, TRAF-6 protein expression was significantly
increased by the presence of SFA treatment (Pb.001), with H-Glc
levels, alone, inducing a more modest but significant rise (Pb.01).
TRAF-6 expression in explants was not as strongly influenced byFig. 2. A–D The mean relative protein expression of IKKβ and NFκB (±S.E.M.) in explants and m
blots shown above. The explants and cells were chronically treated with L-Glc: 5.6 mM or H-Glc
H-Glc alone, for 48 h (n=6; ⁎Pb.05, ⁎⁎Pb.01, ⁎⁎⁎Pb.001).treatment, with only low SFA producing an increase in TRAF6
expression compared with the L-Glc control (Pb.01; Fig. 1E and 1F).
3.2. Effects of chronic treatment with SFA and glucose on IKKβ and NFκB
protein expression
IKKβ protein levels were significantly increased when exposed to
chronic H-Glc alone in both adipose tissue explants (Pb.001) and
isolated adipocytes (Pb.001) compared with control. Both low and
high SFA concentrations induced a significant increase in IKKβ levels,
which remained consistent in the presence of H-Glc in adipose tissue
explants (Pb.01 and Pb.05, respectively; Fig. 2A and 2B). A similar
significant increase in IKKβ was further observed in isolated
adipocytes. In contrast, NFκB protein levels in adipocytes did not
mirror the pattern of expression in the explants. Protein expression in
adipocytes was significantly increased in the presence of low SFA
(Pb.01) and high SFA (Pb.001) treatment, independent of concentra-
tion, whilst H-Glc, alone, induced only a moderate increase (Pb.05).
However, high SFA concentration led to a highly significant increaseature adipocytes compared with their respective controls, with representative Western
: 17.5 mM in combination with low (0.2 mM) and high (2mM) doses of SFAs, as well as
43E.M. Youssef-Elabd et al. / Journal of Nutritional Biochemistry 23 (2012) 39–50in NFκB expression in the adipose tissue explants in the presence of L-
and H-Glc (Pb.001 and Pb.001 respectively; Fig. 2C and 2D).
3.3. Effects of chronic treatment with SFA and glucose on JNK1 and JNK2
protein expression
No statistically significant differences in treatmentswere observed
for either JNK1 or JNK2 protein levels in either adipose tissue explants
or in isolated adipocytes compared with controls (data not shown).
3.4. Effects of chronic treatment with SFA and glucose on TNFα
and IL-6 secretion
In explants high SFA concentration resulted in marked
increases in both IL-6 (Fig. 3A) and TNFα (Fig. 3C) secretion,
independent of glucose concentration, compared with control
(SFA: plus either L-Glc: Pb.05, or H-Glc: Pb.01). Adipocytes
cultured in high SFA concentration showed a similar pattern
(SFA: plus either L-Glc: Pb.01, or H-Glc: Pb.01; Fig 3B and 3D).∗∗
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Fig. 3. (A–D) IL-6 and TNFα fold change in secretion levels (mean±S.E.M.) from control (L-
effect of L-Glc: 5.6 mM or H-Glc: 17.5 mM in combination with low (0.2 mM) and high (2 m
for 48 h (n=6; ⁎Pb.05, ⁎⁎Pb.01, ⁎⁎⁎Pb.001). (a and b) IL-6 control (mean±S.E.M.) Explants
TNFα control (mean±S.E.M.) Exp: 0.30±0.14 pg/ml; Ad: 0.93±0.16 pg/ml.3.5. Effects of intermittent treatment with SFA and glucose on TLR4,
MyD88 and TRAF-6 protein expression
Protein levels of TLR4were significantly increased in both explants
and adipocytes, following 48 h of intermittent treatment with Glc and
SFA (Fig. 4A and 4B), with the exception of L-Glc and low SFA on
adipocytes. Similarly, MyD88 adaptor protein expression increased
with all combinations of Glc and SFA in explants and adipocytes,
excluding L-Glc combined with low and high SFA, respectively, in
adipocytes — although the latter was close to significance at P=.055
(Fig. 4C and 4D). The intermediary signalling molecule, TRAF-6, also
showed increased expression in explants and adipocytes with the
varying treatments of Glc and SFA (Fig. 4E and 4F).
3.6. Effects of intermittent treatment with SFA and glucose on IKKβ and
NFκB protein expression
In the case of IKKβ (Fig. 5A and 5B) and NFκB (Fig. 5C and 5D), all
combinations of Glc and SFA resulted in statistically significant increases∗∗
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Glc: 5.6 mM) and treated explants and adipocytes. Statistical analysis compared the
M) doses of SFAs, as well as H-Glc alone, on secretion of IL-6 and TNFα, respectively,
(Exp): 1212.0±299.22 pg/ml; Adipocytes (Ad): 12798.0±5954.16 pg/ml. (c and d)
Fig. 4. (A–F) The mean relative protein expression (±S.E.M.) of TLR-4, MyD88 and TRAF6 in explants and isolated adipocytes intermittently treated with L-Glc: 5.6 mM or H-Glc: 17.5
mM in combination with low (0.2 mM) and high (2 mM) doses of SFAs, as well as high glucose alone 17.5 mM, for 48 h, compared with controls (n=6; ⁎Pb.05; ⁎⁎Pb.01; ⁎⁎⁎Pb.001).
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Fig. 5. (A–D) The mean relative protein expression (±S.E.M.) of IKKβ and NFκB in explants and isolated adipocytes intermittently treated with L-Glc: 5.6 mM or H-Glc: 17.5
mM in combination with low (0.2 mM) and high (2 mM) doses of SFAs, as well as high glucose alone 17.5 mM, for 48 h, compared with controls (n=6; ⁎Pb.05; ⁎⁎Pb.01;
⁎⁎⁎Pb.001).
45E.M. Youssef-Elabd et al. / Journal of Nutritional Biochemistry 23 (2012) 39–50in protein expression (rangePb.05,Pb.001), although for IKKβ expression,
the increase was more prominent in the adipocytes than the explants.
3.7. Effects of intermittent treatment with SFA and glucose on JNK1 and
JNK2 protein expression
In contrast to the increased levels of TLR4, MyD88, IKKβ and NFκB
proteins, following intermittent treatment with glucose and SFA, no
effect was observed when JNK1 and JNK2 proteins were analysed by
Western blot (data not shown).
3.8. Effects of intermittent treatment with SFA and glucose on TNFα and
IL-6 secretion
3.8.1. 0–12 h
For the duration of 0–12 h, the tissues/cells remained
untreated, resulting in no significant change in TNFα or IL-6
secretion (Figs. 6A, 6E, 7A, and 7E).3.8.2. 12–24 h
Following 12-h treatment with Glc and SFA, at 12–24 h, there
was an obvious increase in TNFα and IL-6 secretion from explants
and adipocytes with high SFA, independent of glucose concentra-
tion, but this was only significant for IL-6 (L-Glc/high SFA: explants
P=.05, adipocytes P=.02; H-Glc/high SFA: explants P=.01, adipo-
cytes P=.006 — although TNFα was often close to significance
(Figs. 6B, 6F, 7B and 7F).
3.8.3. 24–36 h
During the “rest” phase of 24–36 h, in which the tissue and cells
were incubated in low Glc media alone, the explants and cells,
previously treated with high SFA, produced higher levels of IL-6,
irrespective of glucose concentration (L-Glc/high SFA: explants
P=.05; adipocytes P=.016; H-Glc/high SFA: adipocytes P=.004;
Fig. 7C and 7G). However, only high glucose and high SFA
influenced TNFα secretion in adipocytes (P=.04; Fig. 6G).
Fig. 6. (A–H) The fold change in TNFα secretion levels (mean±S.E.M.) from control (L-Glc:5.6 mM) and explants and adipocytes that went through an alternating treatment regime
that consisted of L-Glc for 12 h, then L-Glc: 5.6 mM or H-Glc: 17.5 mM in combination with low (0.2 mM) and high (2 mM) doses of SFAs, as well as H-Glc alone, for a period of 48 h in
total (n=6; ⁎Pb.05). (a) 0–12 h control (mean±S.E.M.) Exp: 0.39±0.18 pg/ml. (b) 12–24 h Control Exp: 0.32±0.13 pg/ml. (c) 24–36 h Control Exp: 0.29±0.15 pg/ml. (d) 36–48
h Control Exp: 0.28±0.13 pg/ml. (e) 0–12 h Control (mean±S.E.M.) Ad: 6.13±1.18 pg/ml. (f) 12–24 h Control Ad: 0.90±0.20 pg/ml. (g) 24–36 h Control Ad: 0.57±0.20 pg/ml. (h) 36–
48 h Control Ad: 0.66±0.23 pg/ml.
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Following a 12-h treatment period (36–48 h), both TNFα and IL-6
levels remained high, overall, with high SFA treatment (Figs. 6D, 6H,
7D, and 7H). However, only IL-6 demonstrated significantly higher
levels in adipocytes treated with low glucose and high SFA compared
with control (P=.03), although several samples were close to
significance (Fig. 7H).
4. Discussion
The current study addressed the hypothesis that chronic over-
nutrition of glucose and dietary lipid may induce long-term
adverse effects via activation of the innate immune response
within human adipose tissue. More specifically, that chronic or
oscillating glucose and SFA levels may activate the adipose tissue
TLR4/NFκB signalling pathway, leading to the production of
downstream proinflammatory adipocytokines. As such, acute
oscillating fluctuation in the cells' nutrient environment mayinduce a chronic, longer lasting proinflammatory response, which,
in turn, could mediate further deleterious consequences for the
progression of metabolic disease.
Our present studies demonstrated that both SFAs and high
glucose exposure up-regulated TLR4 expression in Abd Sc adipose
tissue and isolated Abd Sc adipocytes — a finding consistent with
previous observations in a variety of other cell types [22,29–32].
Both chronic and oscillating treatment regimens significantly
increased expression of TLR4 and the intracellular signalling
molecule, TRAF6. However, chronic and oscillating treatments had
subtle differential effects on the adaptor molecule, MyD88. As such,
chronically treated cell cultures appeared to suppress MyD88
expression whilst oscillating treatment significantly up regulated
the protein. This divergence between the two types of treatment
conditions may occur due to activation of both the MyD88-
dependent and the MyD88 independent pathways, which respond
to the inflammatory insult via TLR4 stimulation [33,34]. These data
suggest that the MyD88 independent pathway is of key importance
Fig. 6 (continued).
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findings highlight that chronically treated adipose cells have
increased pro-inflammatory cytokine release. This indicates that,
whilst intracellularly the cell may aim to desensitise itself to the
insult, in the innate immune pathway there is still a heightened,
continued inflammatory response. In an evolutionary context this
may have been important so that adipose tissue, which resides
underneath the dermal basal layer, may continue to mount a
response to an infection induced by dermal abrasion, whilst the
infection persists. However a systemic based insult may lead to a
disproportional response, as adipose tissue mass expands beyond
its' essential requirements. It should also be stressed that, although
distinct pathways may be invoked, there is still a strong interplay
between the MyD88 dependent and independent pathways, with
TRAF6 being modulated by both signalling systems and therefore
possessing an intermediary role. Stimulation of these MyD88
pathways ultimately results in the activation of IKKβ and NFκB,
the latter of which is a master switch and central regulator of
innate immunity and related functions [35]. The activation of IKKβ
and NFκB is noted by our studies, as adipose cells treated with
either chronic or oscillating culture conditions increased protein
expression of these factors, although interestingly, chronic treat-ment with SFAs had a more pronounced effect on both the
intracellular signal and resulting adipocytokines in both explants
and isolated Abd Sc adipocytes.
In terms of adipocytokines, it was evident that high levels of
SFA had a prominent effect in both the chronic and oscillating
treated cultures. In both instances, secretion of IL-6 and TNFα
followed a similar pattern — although significance was only
observed for both IL-6 and TNFα in the chronically treated
explants and adipocytes. Such data highlights the potential risk of
a continued high fat diet on inducing an inflammatory response,
as it appears to be more pronounced than the glucose induced
response. This would also appear to align with clinical studies
that suggest hyperlipidaemia may impact more significantly over
time than hyperglycaemia in the pathogenesis of metabolic
disease [21].
In addition to our observations on chronically treated cultures,
analysis of adipokine release in the adipose cells undergoing
oscillating treatment demonstrated a form of metabolic memory,
as high SFA treated cultures continued to secrete high levels of IL-
6 in absence of treatment when cultures were exposed to normal
levels of glucose (24–36 h). This observation may, in part, be
attributed to activation of the MyD88 independent pathway, as
Fig. 7. A–H. The fold change in IL-6 secretion levels (mean±S.E.M.) from control (L-Glc:5.6 mM) and explants and adipocytes that went through alternating treatments of L-Glc for 12
h, then L-Glc: 5.6 mM or H-Glc: 17.5 mM in combination with low (0.2 mM) and high (2mM) doses of SFAs, as well as H-Glc alone, for a period of 48 h in total (n=6, p-values: Pb.05⁎).
(a) 0–12 h Control (mean±S.E.M.) Exp: 447.9±160.90 pg/ml. (b) 12–24 h Control (mean±S.E.M.) Exp: 240.22±53.85 pg/ml. (c) 24–36 h Control (mean±S.E.M.) Exp: 193.04±45.16
pg/ml. (d) 36–48 h Control (mean±S.E.M.) Exp: 479.24±247.40 pg/ml. (e) 0–12 h Control (mean±S.E.M.) Ad: 1863.7±95.90 pg/ml. (f) 12–24 h Control Ad: 860.60±272.93 pg/ml. (g)
24–36 h Control Ad: 739.18±221.14 pg/ml. (h) 36–48 h Control Ad: 593.46±193.86 pg/ml.
48 E.M. Youssef-Elabd et al. / Journal of Nutritional Biochemistry 23 (2012) 39–50this mechanism leads to delayed kinetics in the instigation of
NFκB and, hence, the subsequent later onset of IL-6 secretion [36].
Previous studies have also observed this late phase activation of
NFκB in the macrophages of MyD88 knockout mice [37]. The
findings from these and our present studies indicate a system of
inducing a fast, early response to invading pathogens and a late
phase inflammatory response — perhaps to prolong the inflam-
matory defence mechanisms and ensure neutralisation of the
potential pathogen.
The present studies also noted a strong innate immune response
from both the explants and the isolated adipocytes with chronic
and oscillating stimuli. These findings corroborate our previous
studies identifying the importance of the role of the adipocyte
within adipose tissue [23–25,38]. Many studies have suggested that
it is the macrophage within adipose tissue that exerts the defining
inflammatory response, yet it is interesting to note the order of
magnitude in response to SFA or glucose did not differ greatly
between adipose tissue explants and isolated adipocytes. Therefore,
our current findings continue to highlight the importance of theadipocyte and indicate that macrophage infiltration of adipose
tissue, commonly observed in obese/T2DM subjects, may be
initiated by the capacity of the isolated adipocyte to mount an
autonomous immune response to environmental factors. However,
it should be noted that the adipose tissue was not taken from
subjects with either T2DM or a high degree of adiposity, which
could clearly impact on the findings and would be important to
consider in future studies.
These current findings provide evidence that adipose tissue
plays a dynamic role in mechanisms of the innate immune response
in human subjects and provides additional data to our growing
understanding of the inflammatory pathways in adipose tissue and
adipocytes, as well as the factors that activate them [12,39–41].
Irrespective of hyperglycaemic conditions, hyperlipidaemia has a
profound effect on the increased production of the inflammatory
cytokines, ranging from a 30–40-fold increase in TNF-α and IL-6
production, with consistent up-regulation of NFκB components in
human Abd Sc adipose tissue explants and adipocytes. This study
implicates elevated SFAs as a key instigator of the inflammatory
Fig. 7 (continued).
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temporal differences that arise with activation of the TLR4
signalling pathways may once have been advantageous in main-
taining a sustained inflammatory response to endotoxin/invading
pathogens. However, in an environment of continuous dietary
grazing, in which these pathways are stimulated by SFAs and
glucose, there are clear implications for the pathogenesis of
metabolic disease [34,42,43]. Based upon our present in vitro
findings, it is apparent that maintained periods of fasting and
potential change in dietary lipids are required to protect against
sustained inflammation.Acknowledgments
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